Hyehyun Jeong

university of ulsan

H指数:12

被引数:496

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 Trial

SABER研究：局部晚期不可切除胰腺癌采用改良FOLFIRINOX联合或不联合立体定向体部放射治疗的随机开放标签II期临床试验

Annals of Surgical Oncology

IF3.5

2026-05-070

PRE

Prognostic implications of body composition changes in patients with non-metastatic pancreatic adenocarcinoma treated with mFOLFIRINOX

非转移性胰腺腺癌患者接受mFOLFIRINOX治疗后体成分变化的预后意义

Frontiers in Oncology

IF3.3

2026-04-050

OAAI

Ten-Year Follow-up Clinical Outcomes and the Role of Adjuvant Chemotherapy in HER2-Positive Patients with Microinvasive Breast Cancer

Cancer Research and Treatment

IF3.8

2026-01-011

OAAI

Body composition and immunotherapy outcomes in patients with advanced urothelial carcinoma

晚期尿路上皮癌患者的体成分与免疫治疗效果

BMC Cancer

IF3.4

2025-12-030

OAAI

Clinical Characteristics of and Treatment Pattern for EGFR-Amplified Colorectal Cancer

EGFR扩增结直肠癌的临床特征及治疗模式

CANCER RESEARCH AND TREATMENT

IF3.8

2025-10-010

OAAI

Clinical benefit of adjuvant capecitabine according to residual cancer burden in patients with triple-negative breast cancer with residual disease following neoadjuvant chemotherapy

新辅助化疗后仍有残留病灶的三阴性乳腺癌患者中，根据残留肿瘤负荷评价辅助卡培他滨的临床获益

Clinical Breast Cancer

IF2.5

2025-09-190

PRE

Proteogenomic profiling predicts outcomes of adjuvant chemotherapy in extrahepatic cholangiocarcinoma

蛋白质组学分析预测肝外胆管癌辅助化疗的疗效

Journal of Hepatology

IF33

2025-08-110

PRE

Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors

18F-FES PET/CT对接受内分泌治疗联合 cyclin-dependent kinase 4/6 抑制剂治疗的复发性或转移性乳腺癌患者的预测和预后价值

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

IF7.6

2025-01-140

PRE

Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study

EUROPEAN JOURNAL OF CANCER

IF7.1

2024-09-010

PRE

Comprehensive proteogenomic profiling and biomarker analyses in resected extrahepatic cholangiocarcinoma: A prespecified exploratory analysis of the phase 2 STAMP trial

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer

ANNALS OF ONCOLOGY

IF65.4

2023-10-010

Final analysis of the prospective, randomized phase II STAMP trial: Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in node-positive extrahepatic cholangiocarcinoma (CCA)

ANNALS OF ONCOLOGY

IF65.4

2023-10-011

Neoadjuvant endocrine therapy in ER-positive breast cancer: evolution, indication, and tailored treatment strategy

ER阳性乳腺癌的新辅助内分泌治疗: 演变，适应症和量身定制的治疗策略

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

IF4.2

2023-09-292

OAAI

21-gene expression assay and clinical outcomes of premenopausal patients with hormone receptor-positive breast cancer

绝经前激素受体阳性乳腺癌患者21-基因表达检测及临床预后分析

INTERNATIONAL JOURNAL OF CANCER

IF4.7

2023-09-170

Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer

新辅助化疗后HER2变化对HER2-zero和HER2-low乳腺癌患者预后的影响

EUROPEAN JOURNAL OF CANCER

IF7.1

2023-09-0110

Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial

HEPATOLOGY

IF15.8

2023-01-0313

PRE

Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy

EUROPEAN JOURNAL OF CANCER

IF7.1

2022-11-0146

Pathologic complete response, long-term outcomes, and recurrence patterns in HER2-low vs HER2-zero breast cancer after neoadjuvant chemotherapy

ANNALS OF ONCOLOGY

IF65.4

2022-09-010

OAAI

Clinical Outcomes and Effectiveness of Heart Transplantation in Patients With Systemic Light-chain Cardiac Amyloidosis

TRANSPLANTATION

IF5

2022-06-162

Modified Stage Grouping of Diffuse Large B-Cell Lymphoma Involving the Same Side of the Diaphragm in the Rituximab Era

FRONTIERS IN ONCOLOGY

IF3.3

2022-05-270

OAAI

Hyehyun Jeong

个人简介

教育背景

工作经历

荣誉奖项

研究方向